On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology Inc (NASDAQ: MRVL) is the "best when it comes to 5G, the best in high-performance computing.
February 25, 7:21 AM
SVB Leerink analyst Puneet Souda maintains AbCellera Biologics (NASDAQ:ABCL) with a Outperform and lowers the price target from $25 to $20.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 9:06 AM
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization For Treatment Of Mild-To-Moderate COVID-19
February 11, 4:40 PM
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19 Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2,
AbCellera and Its Collaborators Released New Preclinical Data Confirming That the Investigational Antibody Bebtelovimab Maintains Both Full and Potent Neutralization Activity Against the Omicron Variant and All Other Known SARS-COV-2 Variants of Concer…
January 9, 6:00 PM
AbCellera and its collaborators released new preclinical data showing the pseudovirus neutralization status of its two monoclonal antibodies, bamlanivimab and bebtelovimab (also known as LY-CoV1404), against the Omicron variant.